Lyell Immunopharma Inc. (LYEL)
Lyell Immunopharma Statistics
Share Statistics
Lyell Immunopharma has 292.16M shares outstanding. The number of shares has increased by 14.98% in one year.
| Shares Outstanding | 292.16M |
| Shares Change (YoY) | 14.98% |
| Shares Change (QoQ) | 14.12% |
| Owned by Institutions (%) | 50.11% |
| Shares Floating | 124.31M |
| Failed to Deliver (FTD) Shares | 19.4K |
| FTD / Avg. Volume | 1.63% |
Short Selling Information
The latest short interest is 12.4M, so 4.24% of the outstanding shares have been sold short.
| Short Interest | 12.4M |
| Short % of Shares Out | 4.24% |
| Short % of Float | 8.22% |
| Short Ratio (days to cover) | 10.75 |
Valuation Ratios
The PE ratio is -2.08 and the forward PE ratio is -1.35. Lyell Immunopharma's PEG ratio is 0.
| PE Ratio | -2.08 |
| Forward PE | -1.35 |
| PS Ratio | 3745.44 |
| Forward PS | 3191.3 |
| PB Ratio | 0.74 |
| P/FCF Ratio | -2.93 |
| PEG Ratio | 0 |
Enterprise Valuation
Lyell Immunopharma Inc. has an Enterprise Value (EV) of 404.43M.
| EV / Earnings | -1.72 |
| EV / Sales | 3110.98 |
| EV / EBITDA | -1.78 |
| EV / EBIT | -1.64 |
| EV / FCF | -2.43 |
Financial Position
The company has a current ratio of 16.07, with a Debt / Equity ratio of 0.1.
| Current Ratio | 16.07 |
| Quick Ratio | 16.07 |
| Debt / Equity | 0.1 |
| Total Debt / Capitalization | 8.8 |
| Cash Flow / Debt | -2.59 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.36% and return on capital (ROIC) is -34.4%.
| Return on Equity (ROE) | -0.36% |
| Return on Assets (ROA) | -0.31% |
| Return on Capital (ROIC) | -34.4% |
| Revenue Per Employee | 580.36 |
| Profits Per Employee | -1.05M |
| Employee Count | 224 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -76.87% in the last 52 weeks. The beta is -0.36, so Lyell Immunopharma's price volatility has been lower than the market average.
| Beta | -0.36 |
| 52-Week Price Change | -76.87% |
| 50-Day Moving Average | 0.62 |
| 200-Day Moving Average | 1.3 |
| Relative Strength Index (RSI) | 62.77 |
| Average Volume (20 Days) | 1.19M |
Income Statement
In the last 12 months, Lyell Immunopharma had revenue of 130K and earned -234.63M in profits. Earnings per share was -0.93.
| Revenue | 130K |
| Gross Profit | 130K |
| Operating Income | -247.01M |
| Net Income | -234.63M |
| EBITDA | -226.76M |
| EBIT | -247.01M |
| Earnings Per Share (EPS) | -0.93 |
Balance Sheet
The company has 145.65M in cash and 63.17M in debt, giving a net cash position of 82.48M.
| Cash & Cash Equivalents | 145.65M |
| Total Debt | 63.17M |
| Net Cash | 82.48M |
| Retained Earnings | -1B |
| Total Assets | 619.22M |
| Working Capital | 416.53M |
Cash Flow
In the last 12 months, operating cash flow was -163.69M and capital expenditures -2.69M, giving a free cash flow of -166.38M.
| Operating Cash Flow | -163.69M |
| Capital Expenditures | -2.69M |
| Free Cash Flow | -166.38M |
| FCF Per Share | -0.66 |
Margins
Gross margin is 100%, with operating and profit margins of -190.01K% and -180.49K%.
| Gross Margin | 100% |
| Operating Margin | -190.01K% |
| Pretax Margin | -180.49K% |
| Profit Margin | -180.49K% |
| EBITDA Margin | -174.43K% |
| EBIT Margin | -190.01K% |
| FCF Margin | -127.98K% |
Dividends & Yields
LYEL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -130.99% |
| FCF Yield | -80.21% |
Analyst Forecast
The average price target for LYEL is $1, which is 40.8% higher than the current price. The consensus rating is "Hold".
| Price Target | $1 |
| Price Target Difference | 40.8% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -1.57 |
| Piotroski F-Score | 3 |